Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

Inclusion Criteria: * INCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT) * Diagnosis of acute myeloid leukemia (AML), acute biphenotypic leukemia, or acute lymphoblastic leukemia (ALL); CML transformed to blast crisis is eligible * Planned allogeneic HCT using fludarabine phosphate (FLU)/melphalan hydrochloride (MEL) or FLU/busulfan (BU) conditioning * Planned graft versus host disease (GVHD) prophylaxis consisting of tacrolimus (TAC)/methotrexate (MTX) or TAC/sirolimus (SRL) * Human leukocyte antigen (HLA) identical sibling donor, HLA matched unrelated donor, or donor mismatched at 1 HLA allele or antigen * Less than or equal to 5% blasts on bone marrow examination within 60 days of starting conditioning * Age \>= 18 years and =\< 70 years * Able to give informed consent * Subjects will be eligible if their planned conditioning regimen for allogeneic HCT consists of one of the two following standard reduced intensity conditioning regimens: * FLU/MEL: fludarabine phosphate (fludarabine) 120 to 180 mg/m\^2; melphalan hydrochloride (melphalan) =\< 150 mg/m\^2 * FLU/BU: fludarabine 120 to 180 mg/m\^2; busulfan =\< 8 mg/kg orally or =\< 6.4 mg/kg intravenously * Subjects will be eligible if their planned post grafting immunosuppression consists of one of the two following regimens: * TAC/MTX: tacrolimus (oral or intravenous) and intravenous methotrexate administered according to institutional standard practice. * TAC/SRL: tacrolimus (oral or intravenous) and oral sirol…